Suchergebnisse - "Breccia, Massimo"

PubPharm (960)

31

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia : A study from the Registro Italiano LMC and Campus CML

enthalten in: Cancer | 2023

von Tiribelli, M. | Latagliata, R. | Breccia, M. | +38

32

Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice : A GIMEMA Survey

enthalten in: Journal of clinical medicine | 2023

von Breccia, M. | Piciocchi, A. | Abruzzese, E. | +12

33

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

enthalten in: American journal of hematology | 2023

von Lanino, L. | Restuccia, F. | Perego, A. | +63

34

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients : A Real-World PV-NET Study

enthalten in: Cancers | 2023

von Palandri, F. | Rossi, E. | Auteri, G. | +34

35

Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?

enthalten in: Annals of hematology | 2023

von Di Rocco, A. | Di Palma, M. | D’Elia, G. | +5

36

Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?

enthalten in: Annals of hematology | 2023

von Di Rocco, A. | Di Palma, M. | D’Elia, G. | +5

37

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials

enthalten in: Annals of hematology | 2023

von Luciano, L. | Latagliata, R. | Gugliotta, G. | +18

38

Management of Chronic Myeloid Leukemia Patients in Later Lines : The Role of Ponatinib and New Compounds

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Scalzulli, E. | Carmosino, I. | Costa, A. | +3

39

Ruxolitinib in cytopenic myelofibrosis : Response, toxicity, drug discontinuation, and outcome

enthalten in: Cancer | 2023

von Palandri, F. | Breccia, M. | Mazzoni, C. | +37

40

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs : 4-year phase 1 safety and efficacy results

enthalten in: Leukemia | 2023

von Mauro, M. | Hughes, T. | Kim, D. | +23